Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome

Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of many patients with aggressive relapsed or refractory large B-cell lymphoma (LBCL). Treatment can be complicated by clinically evident cytokine release syndrome (CRS), which is characterized by the development of fever...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhaskar, Shakthi T., Patel, Vivek G., Porter, David L., Schuster, Stephen J., Nastoupil, Loretta J., Perales, Miguel-Angel, Tomas, Ana Alarcon, Bishop, Michael R., McGuirk, Joseph P., Maziarz, Richard T., Chen, Andy I., Bachanova, Veronika, Maakaron, Joseph E., Riedell, Peter A., Oluwole, Olalekan O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468356/
https://www.ncbi.nlm.nih.gov/pubmed/36508286
http://dx.doi.org/10.1182/bloodadvances.2022008937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468356/
https://www.ncbi.nlm.nih.gov/pubmed/36508286
http://dx.doi.org/10.1182/bloodadvances.2022008937

Ejemplares similares